LMNGF - BioVaxys initiates ovarian cancer vaccine program in Europe

BioVaxys ([[LMNGF]] +34.4%) has commenced the clinical development program for BVX-0918A, its haptenized tumor antigen vaccine for ovarian cancer. It plans to seek a compassionate use approval in the European Union for Stage III & Stage IV ovarian cancer, followed by submission of an investigational new drug application in the US.The company is in discussions with its designated contract manufacturing organization and anticipates the execution of a manufacturing contract in 1Q of 2021.The Company plans to submit its clinical trial application for BVX-0918A with the European Medicines Agency later this year.BioVaxys intends to develop its vaccine together with a "checkpoint inhibitor" that reduces or decreases the cellular function of an immune checkpoint gene or gene product.The company also recently completed its preclinical program for its SARS-CoV-2 vaccine candidate, BVX-0320.

For further details see:

BioVaxys initiates ovarian cancer vaccine program in Europe